Dr Anait S. Levenson | Prostate Cancer: The Importance of Nutrition in Prevention and Treatment

May 15, 2023 | Engineering & Computer Science, Medical & Health Sciences

Prostate cancer is a leading cause of illness and death in men around the world, and to date, no prevention strategies have been discovered. Dr Anait S. Levenson and a team of cancer researchers from Long Island University in the United States of America are working to advance our understanding of how and why prostate cancer develops. Their important work also demonstrates how compounds found in foods such as grapes and blueberries may help prevent the development and progression of cancer.

Understanding Prostate Cancer

Cancer is a leading cause of death worldwide. In the United States of America, 1,898,160 new cancer cases and 608,570 cancer deaths were projected for 2021 but the reality for prostate cancer was even starker – an alarming increase was seen for both new cases and deaths.

There is currently no treatment available to prevent this type of cancer and 30% of men with risk factors placing them under active surveillance for prostate cancer develop more aggressive disease requiring intensive treatment such as surgery and hormone therapy (chemical castration), which have devastating effects on the individual and their quality of life.

As a result, scientists and healthcare professionals are dedicated to further understanding the pathways leading to prostate cancer and discovering new ways to prevent this disease. Dr Anait S. Levenson from Long Island University in the United States of America is one of the scientists driving a new understanding of the impact of diet on prostate cancer progression and prevention.

Understanding the underlying pathways of cancer progression is key to being able to optimise diagnostics, improve treatment and develop new medicines. Dr Levenson and her team are particularly interested in the molecular and genetic mechanisms of prostate cancer development and progression. To date, the team’s research has focussed on the MTA1 protein, an epigenetic molecule which is highly expressed in several types of cancer, including prostate cancer.

It is now known that MTA1 is involved in multiple stages of prostate cancer including inflammation, tumour growth and invasion. In addition to regulating survival pathways through various epigenetic modulations, MTA1 can impact molecules called microRNAs (miRNAs for short) which control multiple cancer development pathways, including enhancing cancer progression and the ability of the cancer cells to spread (a process known as metastasis). Dr Levenson and her team highlighted the role of MTA1 in prostate cancer progression by studying mice genetically modified to overproduce MTA1. Their research showed that mice with higher levels of MTA1 were more likely to develop cancerous prostate cells than mice with normal MTA1 levels.

Illustration of healthy prostate and cancerous prostate

Diet and Cancer Prevention

Although the link between a person’s diet and cancer risk is complicated, data have linked a diet high in dairy and fats with an increased risk of prostate cancer. More recently, diets high in certain fruits, vegetables, and soy foods have been associated with a decreased risk of prostate cancer.

As prostate cancer is an age-related and slow-growing disease likely influenced by nutrition, the use of diet for prevention and as an intervention alongside conventional treatment has huge potential. Nutrition-based intervention is a particularly exciting prospect given that there are currently no other preventative actions or treatment options available.

Most modern medicines are based on naturally occurring compounds. Currently, scientists around the world are investigating the effects of diets high in these compounds as well as how these natural compounds can be modified to make more effective medicines.

Dr Levenson’s team is currently investigating the preventive and therapeutic potential of naturally occurring compounds called polyphenols, which are found in plant-based foods such as fruits, vegetables, tea and dark chocolate. Previous studies have linked diets high in these compounds with a lower risk of developing cancer.

Importantly, Dr Levenson’s research has focused on a type of polyphenol produced by certain plants when under environmental stress. These polyphenols, called stilbenes, are known to have antioxidant, anti-inflammatory, antimicrobial and anti-tumour properties. There are over 400 types of natural stilbenes which can be found in foods such as grapes (including wine), blueberries and peanuts.

Dr Levenson’s team is currently working on resveratrol (which comes from grapes and is probably the most well-known stilbene), pterostilbene (which comes from blueberries), and gnetin C (which comes from the melinjo plant, commonly used in Indonesian food).

While the exact mechanisms underlying the beneficial effects of stilbenes are not yet completely understood, Dr Levenson’s team has shown how stilbenes can protect against prostate cancer by targeting MTA1 and altering miRNAs, leading to tumour-suppressing genes being turned on and thus, cancer progression and inflammation pathways being slowed down.

Grapes and blueberries contain high levels of stilbenes

Stilbenes in Practice

In 2013–15, Dr Levenson’s team treated prostate cancer cells in the lab with resveratrol (a polyphenol found in grapes and wine) and pterostilbene (a polyphenol found in blueberries). They discovered that these compounds suppressed the growth rate of tumour cells and that pterostilbene was more potent than resveratrol in inhibiting MTA1.

Following on from this, the team treated mice which were genetically modified to overproduce MTA1 with a pterostilbene-supplemented diet. They found that the mice with higher levels of MTA1 were more likely to develop cancerous prostate cells than mice with normal MTA1 levels. They also discovered that the mice who had eaten a pterostilbene-supplemented diet had reduced levels of MTA1, and certain miRNAs, and subsequently, showed fewer cancerous prostate cells.

In 2020, the team added grape powder (which contains both resveratrol and pterostilbene) to the diet of mice who were genetically predisposed to developing prostate cancer. They found that the mice who were treated with grape powder had lower levels of tumour-causing miRNAs and that these mice had less abnormal prostate cell growth.

Less is known about gnetin C, a resveratrol dimer, most commonly found in the melinjo plant, which is part of Indonesian cuisine. In an impressive series of experiments, Dr Levenson’s team treated mice with prostate overexpressing MTA1 with gnetin C, resveratrol, and pterostilbene, and found that gnetin C was much more efficient at slowing tumour progression than either of the other two compounds.

By analysing the prostate tissue, the team could see that gnetin C slowed the progression of prostate cancer by reducing cell division, inflammation, and the formation of new blood vessels and by inducing cell death (apoptosis). These studies highlight the role that MTA1 and miRNAs play in prostate cancer development and demonstrate that dietary stilbenes can reduce prostate cancer progression.

Dr Levenson’s findings have exciting implications for the future of prostate cancer prevention and treatment. The team’s latest findings show how including more stilbene-containing foods in our diets may help protect both the general population and ‘at risk’ patients from prostate cancer. In a recent publication, Dr Levenson stated ‘A substantial portion of prostate cancer cases could be prevented by applying effective “prostate cancer-specific diets” that contain bioactive dietary polyphenols and micronutrients’.

The Future of Stilbenes

Whilst there have not yet been any human trials on the effect of stilbenes on prostate cancer development, the future of these compounds is bright as the evidence increases to support their use to prevent and treat cancer. These natural dietary compounds have been shown to protect against prostate cancer in mice, and remarkably, they have been shown to make drug-resistant cancer cells in the laboratory sensitive to treatment again. Whilst the significant amounts of stilbenes in foods such as blueberries and grapes may help to prevent cancer from developing, the ability to modify these natural substances into potent anticancer drugs is a thrilling development in the quest to provide better outcomes for cancer patients.

SHARE

DOWNLOAD E-BOOK

REFERENCE

https://doi.org/10.33548/SCIENTIA895

MEET THE RESEARCHER


Dr Anait S. Levenson, MD, PhD

College of Veterinary Medicine
Long Island University
Brookville, NY
United States of America

Dr Anait S. Levenson obtained her medical degree from the Second Moscow State Medical Institute and then went on to receive a PhD in Clinical Immunology from the Institute of Tuberculosis, Moscow. Dr Levenson’s interests lie in cancer research and pharmacology. Her research group focuses on understanding the molecular and genetic pathways leading to prostate cancer progression and metastasis, as well as investigating the potential of natural dietary compounds known as stilbenes for cancer prevention and treatment. Dr Levenson is an internationally recognised leader in nutritional cancer chemoprevention, and she has published over 60 journal articles and seven book chapters. She is an active member of several leading professional societies including the American Association for Cancer Research, the New York Academy of Sciences, and the American Council for Medicinally Active Plants where she served as President for two years (2020–2022).

CONTACT

E: Anait.Levenson@liu.edu

W: https://liu.edu/VetMed/Research/~/link.aspx?_id=9461DEF1473B4953861BDD44D6CAB276&_z=z

KEY COLLABORATORS

Dr Avinash Kumar, PhD, Long Island University, Brooklyn, United States of America

Dr Swati Dhar, PhD, NeilImmuneTech, Inc, Chicago, United States of America

Dr Agnes M Rimando, PhD, United States Department of Agriculture (sadly deceased in 2018)

Dr Janice M Lage, MD, St. Michael’s Hospital, Toronto, Canada

Thanks are also given to the numerous students, laboratory members and collaborators who have supported this research over the years 

FUNDING

National Institutes of Health/National Cancer Institute

Department of Defence Prostate Cancer Research Program

The California Table Grape Commission

FURTHER READING

R Hemani, I Patel, N Inamdar, et al., Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer, Cancer Prevention Research, 2022, 15(2), 87–100. DOI: https://doi.org/10.1158/1940-6207.CAPR-21-0242

P Parupathi, G Campanelli, RA Deabel, et al., Gnetin C Intercepts MTA1-Associated Neoplastic Progression in Prostate Cancer, Cancers, 2022, 14(24), 6038. DOI: https://doi.org/10.3390/cancers14246038

T Joshi, Patel I, Kumar A, et al., Grape powder supplementation attenuates prostate neoplasia associated with Pten haploinsufficiency in mice fed high-fat diet, Molecular Nutrition & Food Research, 2020, 64(16), e2000326. DOI: https://doi.org/10.1002/mnfr.202000326

S Dhar, A Kumar, L Zhang, et al., Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer, Oncotarget, 2016, 7(14), 18469-84. DOI: https://doi.org/10.18632/oncotarget.7841

S Dhar, A Kumar, AM Rimando, et al., Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer, Oncotarget, 2015, 6(29), 27214–26. DOI: https://doi.org/10.18632/oncotarget.4877

REPUBLISH OUR ARTICLES

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence (CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

SUBSCRIBE NOW


Follow Us

MORE ARTICLES YOU MAY LIKE

Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia

Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia

For millions of men, ageing brings with it a set of frustrating and often disruptive urinary symptoms. These symptoms, caused by benign prostatic hyperplasia, or BPH, can affect sleep, confidence, and overall quality of life. Traditionally, treatment follows a familiar path. Patients begin with medications, often for years, and may eventually progress to surgery if symptoms worsen. Yet this pathway is not without its drawbacks. Medications can cause side effects, while surgery carries risks and recovery time. In recent years, a minimally invasive interventional radiology procedure called prostate artery embolisation, or PAE, has begun to challenge this traditional model. At the forefront of this shift is a collaborative research group, led by Dr. Nicholas Brown of the University of Queensland, whose series of P-EASY studies has explored whether PAE could transform how BPH is treated, particularly at earlier stages.

Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach

Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach

Recurrent Aphthous Stomatitis (RAS) is an oral condition characterized by one or several painful mucosal ulcers. RAS affects a large proportion of the population and has a point prevalence of approximately 2–3%, daily. The etiology remains unknown, and there is currently no curative treatment. Most patients experience recurring episodes over time, with each episode typically lasting up to a week. Here, we describe the development of a mucoadhesive patch which, when applied over a RAS ulcer, provides rapid pain relief. The patch is easy for patients to apply when symptoms begin and has the potential to be used as an over-the-counter product. The development of the Mucocort mucoadhesive patch is an example of a Close-to-Market innovation strategy that embraces simplicity within a complex healthcare system. By simplifying the product concept, the team has reduced the number of regulatory steps required before market approval. This MedTech/Pharma innovation model, known as the “4R” framework – Re-purposing, Re-formulation, Re-positioning, and Re-patenting – has guided the program from concept to commercialization. In addition to the biodegradable mucoadhesive patch developed for RAS ulcers, the team is extending the innovation concept to a mucoadhesive gel formulation for the prevention and treatment of chemotherapy-induced mucositis. This gel-based program is being commercialized separately through MucoShield.

The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care

The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care

Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease headon. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition.

Ms. Aikaterini Dritsoula | Looking Beyond Snoring: How Hidden Airway Problems Shape Children’s Sleep

Ms. Aikaterini Dritsoula | Looking Beyond Snoring: How Hidden Airway Problems Shape Children’s Sleep

For many parents, a child’s snoring may seem harmless, even endearing. Yet in some cases, it signals something more serious. Obstructive sleep apnoea is a condition in which a child’s breathing is repeatedly disrupted during sleep. These interruptions can affect growth, behaviour, and learning. Children with this condition may toss and turn at night, struggle to concentrate during the day, or show signs of hyperactivity and fatigue. Traditionally, enlarged tonsils and adenoids have been seen as the main culprits. Surgery to remove them has long been considered the standard treatment. However, research led by Consultant ENT Surgeon Ms. Aikaterini Dritsoula of The Leeds Teaching Hospitals NHS Trust invites us to look deeper. Her work suggests that the story is often more complex, especially in very young children.